Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · May 02, 2022

Negligible Impact of Thiopurine Exposure on Immunogenicity to Infliximab in the Setting of Elevated Infliximab Concentrations

Inflammatory Bowel Diseases

 

Additional Info

Disclosure statements are available on the authors' profiles:

Inflammatory Bowel Diseases
Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations
Inflamm. Bowel Dis. 2022 Mar 30;28(4)649-651, RC Ungaro, JF Colombel, MC Dubinsky, A Jain, T Dervieux

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading